BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding 'Business Responsibility & Sustainability Report'.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals submitted its BRSR for FY25 along with its annual report, as required under SEBI's listing rules. The Hyderabad-based company is engaged entirely in international wholesale distribution of pharmaceutical products, with 100% of turnover coming from exports and no in-house manufacturing currently. Key financials disclosed include a turnover of Rs. 6,098.82 lakhs and net worth of Rs. 12,785.27 lakhs. The company has 48 permanent employees, a board with 6 directors (2 women), 8 overseas subsidiaries, and plans to launch its own manufacturing plant in H1 FY26, moving away from its current asset-light model. A Rs. 1.35 lakh plus GST fine was paid to NSE for a 27-day delay in appointing a woman independent director. No independent assurance was obtained for the BRSR.
This is a routine annual regulatory disclosure, not a stock-moving event. The fine is minor and already paid. The more relevant takeaway for shareholders is the planned manufacturing plant launch in H1 FY26, which signals a shift from distribution-only to a hybrid model that could impact future margins and capital needs.